Sursum schreef op 4 juni 2020 16:53:
Study Type: Interventional (Clinical Trial)
Estimated Enrollment: 120 participants
Intervention Model: Parallel Assignment
Intervention Model Description: Randomized, open-label, parallel-group, controlled, multi-center clinical trial
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19: a Randomized, Parallel-group, Open-label, Multi-center Pilot Trial (PROTECT-COVID-19).
Estimated Study Start Date : June 2020
Estimated Primary Completion Date : June 2021
Estimated Study Completion Date : July 2021 clinicaltrials.gov/ct2/show/NCT044146...